Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
about
The 26S proteasome is a multifaceted target for anti-cancer therapiesDrugging the unfolded protein response in acute leukemiasAdvances in the understanding of mechanisms and therapeutic use of bortezomibHomopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyPSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancerDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaTranscription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cellsMolecular mechanisms of bortezomib resistant adenocarcinoma cellsBAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaDifferential regulation of polysome mRNA levels in mouse Hepa-1C1C7 cells exposed to dioxinFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line.A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Effect of noncompetitive proteasome inhibition on bortezomib resistance.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsThe pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoEstablishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosisTargeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin OncologyThe resistance mechanisms of proteasome inhibitor bortezomib.Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibA novel role of proteasomal β1 subunit in tumorigenesis.HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoBortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationProteasome inhibitors in the treatment of multiple myelomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
P2860
Q26795764-542C4C62-12B9-4B5D-B574-7CC46EC1E62FQ26801114-38DC6E41-CA2D-402C-98FD-8C051AD1A456Q26849940-4DEF5200-266E-4860-B26C-1DA82E500F61Q27677425-9292C599-E03F-4AFA-B6E4-50D184C68C6EQ28080999-1D6FFB13-A16A-495A-89FA-54FA3261FFF1Q28082910-437910CE-03E0-4312-88EA-9B41EBBE67E0Q28267716-FC681371-1684-4A20-95A4-979D6E98968DQ28271286-1487688B-69A4-4075-81EE-56F9780BA951Q28279454-839D20F0-656B-40B0-B465-8FEE38086D51Q28478538-0E2E93F0-6713-483D-B018-7124C1736C04Q28533736-AE229B3C-8F58-456C-9E70-56E5B2308A2DQ28740988-01367C5A-46CB-435C-BD5E-597C25CBA022Q30490975-BE109357-D599-442F-B6A0-6F6B5F81BBB9Q31031641-352F44D7-D6BF-4017-AF54-558CB99A6114Q33387006-4948E320-AA74-42D4-8EC3-2DEF7B8178D4Q33523956-AAB8CA12-2698-45F4-93F5-B922FAA362D7Q33556178-6DEA122D-C789-4D17-A1EB-1327847A5BD7Q33585280-87A7A5C9-FD2F-4B32-986D-B214A67925DEQ33588424-859ECBB2-9A27-4762-9C90-06ABED308ED3Q33627312-A09BFBE3-C916-4FC9-916B-4BF53FBA67DBQ33742779-A2B26F86-3FE8-4700-8659-247712EC0296Q33758880-E04F54E9-E693-443D-B3FD-7D78BD18411DQ33761796-1C8C97E7-61A2-478C-965C-70CE648CDBCFQ33896749-A827B4CC-3BA8-447F-872D-BB577FF725F0Q34179925-6877BC5E-2455-41DF-BE6E-D740D94BC3A8Q34195083-953DFECE-D9EC-4BEA-9A02-99E1249AD563Q34227679-4ECF7FB0-0B3B-44A3-81C7-37EBFF43B9ACQ34245549-C04407F1-6E46-47C1-877B-8E3F9122BA37Q34256126-AFF07EE2-EEEF-4055-BF7B-8DA787B4F0C7Q34289909-74928D2A-192A-464F-ACD1-CA63FBD6107DQ34317307-67C4DF33-C170-4CA7-8D32-D72D80558458Q34347861-A307E421-E415-429C-9036-88148386A1C0Q34534191-D5D546BD-3BC1-472E-8231-89EBB974E2BCQ34542087-DCFC0ACB-B5FC-4C40-A06F-C10E60B7D5A5Q34611676-E7FDF190-7924-4439-8A30-B39A44FFDE4DQ34788381-B7BD634E-831F-4552-BE95-716227F3239CQ34870566-B482A3BF-7D7E-4240-8678-5D7E9AC4D275Q34924231-6534539B-BB9A-4EB1-B3CD-3386C27CB036Q35009005-94C6D959-B625-4C4B-845C-D576CD65B1A9Q35024457-28575F34-D1A7-4297-9E8B-1EF39A0E8B7A
P2860
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Molecular basis of bortezomib ...... erexpression of PSMB5 protein.
@en
Molecular basis of bortezomib resistance: proteasome subunit beta5
@nl
type
label
Molecular basis of bortezomib ...... erexpression of PSMB5 protein.
@en
Molecular basis of bortezomib resistance: proteasome subunit beta5
@nl
prefLabel
Molecular basis of bortezomib ...... erexpression of PSMB5 protein.
@en
Molecular basis of bortezomib resistance: proteasome subunit beta5
@nl
P2093
P1433
P1476
Molecular basis of bortezomib ...... erexpression of PSMB5 protein.
@en
P2093
Ben A C Dijkmans
Celia R Berkers
Clara Lemos
George L Scheffer
Gerrit Jansen
Gertjan L Kaspers
Godefridus J Peters
Ina van Zantwijk
Jacqueline Cloos
Joost W van der Heijden
P304
P356
10.1182/BLOOD-2007-08-104950
P407
P50
P577
2008-06-18T00:00:00Z